Aquestive Therapeutics (NASDAQ:AQST) Announces Earnings Results

Aquestive Therapeutics (NASDAQ:AQST) announced its quarterly earnings data on Tuesday. The company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.08, Yahoo Finance reports. The business had revenue of $20.10 million during the quarter, compared to analysts’ expectations of $12.62 million. During the same quarter in the previous year, the firm earned ($0.10) earnings per share. Aquestive Therapeutics updated its FY 2024 guidance to EPS.

Aquestive Therapeutics Price Performance

NASDAQ:AQST traded up $0.14 during midday trading on Friday, hitting $3.43. The company’s stock had a trading volume of 1,945,651 shares, compared to its average volume of 1,935,842. Aquestive Therapeutics has a fifty-two week low of $1.25 and a fifty-two week high of $6.23. The firm’s 50 day moving average is $2.91 and its 200-day moving average is $3.36. The firm has a market cap of $312.26 million, a P/E ratio of -8.17 and a beta of 2.80.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. Leerink Partnrs upgraded shares of Aquestive Therapeutics to a “strong-buy” rating in a research report on Friday, May 10th. Piper Sandler assumed coverage on shares of Aquestive Therapeutics in a research report on Thursday, April 11th. They set an “overweight” rating and a $10.00 price objective on the stock. JMP Securities reiterated a “market outperform” rating and set a $9.00 price target on shares of Aquestive Therapeutics in a report on Wednesday, June 26th. SVB Leerink assumed coverage on shares of Aquestive Therapeutics in a research report on Friday, May 10th. They set an “outperform” rating and a $8.00 target price on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price target on shares of Aquestive Therapeutics in a research report on Friday, July 26th. Six investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $7.83.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.